What diagnostic evaluation and management are recommended for a 37‑year‑old man with 18‑pound unintentional weight loss over 15 months, an 11‑month history of epigastric pain that worsens on an empty stomach, previously treated Helicobacter pylori infection, fatigue, occasional leg cramps, loose foul‑smelling stools, halitosis, and a cholecystectomy performed two months ago?

Diagnostic Evaluation and Management for a 37-Year-Old Man with Unintentional Weight Loss and Chronic Epigastric Pain

This patient requires urgent upper endoscopy with biopsies, comprehensive malabsorption workup including celiac serology and fecal elastase, and nutritional assessment given the constellation of significant unintentional weight loss (18 pounds over 15 months), malabsorptive symptoms (foul-smelling stools), and persistent epigastric pain despite prior H. pylori treatment.

Immediate Diagnostic Priorities

Endoscopic Evaluation

• Urgent (not 2-week-wait) upper endoscopy is mandatory because this patient has new-onset unintentional weight loss, which constitutes an alarm feature requiring investigative workup 1.
• The diagnostic yield of endoscopy in patients with unintentional weight loss plus additional gastrointestinal symptoms is substantial (10% clinically significant findings in upper endoscopy), particularly in patients with multiple symptoms beyond isolated weight loss 2.
• During endoscopy, obtain gastric and duodenal biopsies even if mucosa appears normal, given the malabsorptive picture and need to exclude microscopic pathology 3.

Essential Laboratory Workup

• Full blood count is required for all patients ≥25 years presenting with dyspepsia to exclude anemia or occult pathology 1.
• Celiac serology (tissue transglutaminase IgA with total IgA) is indicated when dyspepsia coexists with IBS-type symptoms (loose stools) to rule out gluten-sensitive enteropathy 1.
• Fecal elastase to evaluate for pancreatic exocrine insufficiency, which would explain the foul-smelling stools, weight loss, and fat-soluble vitamin deficiency (leg cramps suggest possible hypocalcemia/hypomagnesemia).
• Nutritional markers: vitamin B12, folate, iron studies, 25-OH vitamin D, magnesium, and calcium to assess malabsorption severity.

H. pylori Reassessment

• Confirm H. pylori eradication with urea breath test or stool antigen test (not serology), as symptoms persisting after treatment may indicate treatment failure 4, 5.
• If eradication was not confirmed after initial treatment, this represents a critical gap—only 50% of patients receive post-treatment testing despite guideline recommendations 6.
• If H. pylori persists, treat with 14-day bismuth quadruple therapy (PBMT-14: PPI/bismuth/metronidazole/tetracycline) or 14-day concomitant therapy (PACM-14: PPI/amoxicillin/clarithromycin/metronidazole), which achieve 88.3% and 89.8% eradication rates respectively 4, 7.
• Avoid repeating the same regimen previously used, as this reduces eradication rates by approximately 50% 7.

Differential Diagnosis Considerations

Malabsorption Syndromes (Primary Concern)

• Celiac disease must be excluded given the combination of weight loss, diarrhea, and potential nutrient deficiencies (leg cramps) 1.
• Pancreatic exocrine insufficiency is highly plausible post-cholecystectomy with foul-smelling stools and weight loss.
• Small intestinal bacterial overgrowth (SIBO) can cause similar symptoms and may be evaluated with glucose or lactulose breath testing if initial workup is unrevealing.

Post-Cholecystectomy Syndrome

• The cholecystectomy 2 months ago may be contributing to bile acid malabsorption, causing diarrhea and potentially worsening malabsorption.
• Consider empiric trial of bile acid sequestrant (cholestyramine) if other causes excluded.

Functional Dyspepsia with Overlap

• While up to 50% of functional dyspepsia patients have overlapping IBS-diarrhea 1, functional dyspepsia remains a diagnosis of exclusion and cannot be confirmed until organic pathology is ruled out 8.
• The epigastric pain worsening on empty stomach suggests peptic ulcer disease pattern, making endoscopy even more critical 1, 8.

Management Algorithm

Step 1: Complete Diagnostic Workup (Within 2-4 Weeks)

1. Upper endoscopy with gastric and duodenal biopsies
2. Full blood count, celiac serology, fecal elastase
3. H. pylori test-of-cure (breath or stool antigen)
4. Nutritional markers (B12, folate, iron, vitamin D, magnesium, calcium)

Step 2: Treat Identified Pathology

• If H. pylori positive: Treat with 14-day PBMT-14 or PACM-14, avoiding previously used regimen 4, 7.
• If celiac disease confirmed: Strict gluten-free diet with dietitian consultation.
• If pancreatic insufficiency: Pancreatic enzyme replacement therapy titrated to symptom response.
• If endoscopy shows peptic ulcer: PPI therapy for 8 weeks minimum 8.

Step 3: Nutritional Repletion

• Replace identified deficiencies (iron, B12, vitamin D, magnesium, calcium).
• Consider nutritional supplementation if severe malabsorption confirmed.

Step 4: Symptomatic Management (Only After Organic Causes Excluded)

• If all investigations normal: 8 weeks of PPI therapy for persistent epigastric pain 1, 8.
• Low-FODMAP diet trial for persistent diarrhea 8.
• If PPI fails, consider tricyclic antidepressants (e.g., amitriptyline 10-25 mg nightly) followed by prokinetics 8.

Critical Pitfalls to Avoid

• Do not diagnose functional dyspepsia without completing full malabsorption workup—the foul-smelling stools and weight loss demand exclusion of celiac disease and pancreatic insufficiency 1, 8.
• Do not assume H. pylori was successfully eradicated without documented test-of-cure; treatment failure rates are substantial, and only 50% of patients receive appropriate follow-up testing 6.
• Do not delay endoscopy in a patient with unintentional weight loss; this is an alarm feature requiring prompt investigation 1, 2.
• Do not repeat the same H. pylori regimen if retreatment is needed, as this halves the eradication rate 7.
• Review prior antibiotic exposures before selecting H. pylori therapy—previous macrolide use reduces clarithromycin-based regimen efficacy by 32%, and prior metronidazole use reduces metronidazole-based regimen efficacy by 39% 7.